Evaluation of 90Y phosphate particles as a possible radiation synoviorthesis agent

Abstract

The promising results warrant further studies on 90Y phosphate particles for use in radiation synovectomy.

Bioevaluation of 90Y-labeled particles in animal model of arthritis

“…All 90 Y-labeled preparations were made following the methods reported by us earlier [17,18], except for certain experimental details. A brief description of the methods followed is given here.…”

“…Hence, 90 Y-labeled hydroxyapatite of suitable size was conceived in our laboratory and evaluated for its use in radiosynoviorthesis [17]. Since the preparation of 90 Y-hydroxyapatite involves multiple steps, use of 90 YPO 4 which is much easier to prepare, was also explored [18].…”

Radiolanthanide-loaded agglomerated Fe3O4nanoparticles for possible use in the treatment of arthritis: formulation, characterization and evaluation in rats

“…1 Ablation of the synovium can be accomplished through a number of surgical and non-surgical procedures including laser surgery, use of chemicals such as osmic acid rifampicin, and use of ionizing radiation by intra-articular administration of b À emitting radionuclides in a suitable chemical formulation. 2,[11][12][13][14][15][16][17][18][19][20][21][22][23][24] This is principally due to the availability of a wide variety of therapeutically useful b À emitting radionuclides among lanthanide elements having a wide range of energy (0.34-2.28 MeV). [2][3][4][5][6][7][8][9] While a myriad of factors contribute to the utility of RSV, selection of an appropriate b À emitting radionuclide of optimum tissue penetration range along with desirable radioactive decay a Isotope Production and Applications Division, Bhabha Atomic Research Centre, characteristics is a key determinant that underpins its success.…”

Erbium-169 labeled hydroxyapatite particulates for use in radiation synovectomy of digital joints – a preliminary investigation

“…Apart from this, another major challenge in the RSV procedure is to minimize the non-target dose to the organs, such as, liver, spleen, lymph nodes, due to the leakage of radioactivity from the synovial cavity [6,8,15,16]. The leakage usually occurs either due to inappropriate size of the particulates or due to the poor in vivo stability of the preparation leading to the dissociation of activity from the particles [6,8,[15][16][17]. The majority of radiolabeled agents used in RSV are either radiocolloid or radiolabeled macroaggregates.…”